Notice of Application - 2007
FR Doc E7-12971 [Federal Register: July 5, 2007 (Volume 72, Number 128)] [Notices] [Page 36730-36731] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr05jy07-118]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 29, 2007, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:
| Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| Aminorex (1585) |
I |
| Alpha-ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide (7315) |
I |
| Tetrahydrocannabinols (7370) |
I |
| 4-Bromo-2,5-dimethoxyamphetamine (7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) |
I |
| 2,5-Dimethoxyamphetamine (7396) |
I |
| 3,4-Methylenedioxyamphetamine (7400) |
I |
| N-Hydroxy-3,4-methylenedioxyamphetamine (7402) |
I |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404) |
I |
| 3,4-Methylenedioxy methamphetamine (MDMA)(7405) |
I |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470) |
I |
| 1-Benzylpiperazine (BZP) (7493) |
I |
| Heroin (9200) |
I |
| Normorphine (9313) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Nabilone (7379) |
II |
| 1-Phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Diprenorphine (9058) |
II |
| Ecgonine (9180) |
II |
| Levomethorphan (9210) |
II |
| Levorphanol (9220) |
II |
| Meperidine (9230) |
II |
| Metazocine (9240) |
II |
| Methadone (9250) |
II |
| Morphine (9300) |
II |
| Thebaine (9333) |
II |
| Levo-alphacetylmethadol (9648) |
II |
| Carfentanil (9743) |
II |
| Fentanyl (9801) |
II |
The company plans to manufacture reference standards. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-12971 Filed 7-3-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO).
|
